Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
84 hedge funds and large institutions have $203M invested in Concert Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 13 closing their positions.
401% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $224K
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
5% more funds holding
Funds holding: 80 → 84 (+4)
1.66% more ownership
Funds ownership: 70.73% → 72.39% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $227M → $203M (-$24.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.63M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.86M |
| 4 |
BlackRock
New York
|
+$2.16M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$14.4M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$5.93M |
| 3 |
AG
Artal Group
Luxembourg
|
-$3.84M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$2.26M |
| 5 |
Morgan Stanley
New York
|
-$1.99M |
CNCE Hedge Fund Activity: Q4 2022 in Review
84 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2022, worth a combined $203M — down 11% from $227M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CNCE positions and 13 closed out — a net gain of 5 holders — while 27 added to existing stakes and 24 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $14.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $14.4M sold.
- 84 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2022, up from 80 in Q3 2022.
- Funds reported $203M of Concert Pharmaceuticals, Inc. stock for Q4 2022, down 11% quarter-over-quarter.
- 18 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2022 and 13 closed out, a net change of +5 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2022 was Kynam Capital Management, an estimated $14.4M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2022 was Perceptive Advisors, an estimated $14.4M sold.
Based on aggregated 13F filings for Q4 2022.